CRMD BREAKING NEWS: ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages CorMedix Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – CRMD
August 17, 2021 12:03 ET
|
The Rosen Law Firm PA
NEW YORK, Aug. 17, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CorMedix Inc. (NASDAQ: CRMD) between July 8, 2020 and...
ARDX INVESTOR NEWS: ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – ARDX
August 13, 2021 18:15 ET
|
The Rosen Law Firm PA
NEW YORK, Aug. 13, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ardelyx, Inc. (NASDAQ: ARDX) between August 6, 2020 and...
ROSEN, A LONGSTANDING LAW FIRM, Encourages Iterum Therapeutics plc Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – ITRM
August 11, 2021 19:45 ET
|
The Rosen Law Firm PA
NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Iterum...
Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 10, 2021 08:05 ET
|
Vallon Pharmaceuticals Inc.
- Company continues to drive enrollment in pivotal intranasal abuse study evaluating ADAIR toward completion before year-end 2021 - ADAIR targeting the large and growing Adderall® segment of the...
Acer Therapeutics and Relief Therapeutics Announce Submission of a New Drug Application to the U.S. FDA for ACER-001 for Treatment of Urea Cycle Disorders
August 09, 2021 08:30 ET
|
Acer Therapeutics Inc.
NEWTON, Mass. and GENEVA, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”), a pharmaceutical company focused on the acquisition, development and commercialization of...
Arcutis Announces Second Quarter 2021 Financial Results and Provides Business Update
August 05, 2021 16:05 ET
|
Arcutis Biotherapeutics, Inc.
Anticipates submission of a New Drug Application (NDA) for topical roflumilast cream as a potential treatment for plaque psoriasis late in the third quarter or early in the fourth quarter of...
ROSEN, A RESPECTED AND LEADING LAW FIRM, Encourages Ardelyx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – ARDX
August 03, 2021 15:45 ET
|
The Rosen Law Firm PA
NEW YORK, Aug. 03, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages CorMedix Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline – CRMD
July 28, 2021 09:49 ET
|
The Rosen Law Firm PA
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
Axsome Therapeutics Announces Planned NDA Submission for AXS-14 for the Management of Fibromyalgia
June 15, 2021 07:00 ET
|
Axsome Therapeutics, Inc.
Submission anticipated in 4Q 2022 NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the...
Axsome Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for AXS-05 for Treatment of Major Depressive Disorder
April 26, 2021 06:00 ET
|
Axsome Therapeutics, Inc.
FDA grants Priority Review and sets PDUFA action goal date of August 22, 2021 NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company...